Immunogenicity Induced by COVID-19 Vaccines in Mexican Population

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population: mRNA Expression for IgG Anti-spike

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06597370

Acronym

Vaccines COVID

Enrollment

Registered

2024-09-19

Start date

2021-09-01

Completion date

2021-12-21

Last updated

2024-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Vaccine

Brief summary

To determine the gene expression of anti-spike IgG through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Detailed description

80 subjects with full vaccination schedule will be included, 20 per group To know the gene expression of IgG anti-spike through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Interventions

OTHERGene expression mRNA of IgG anti-spike

b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule. c) Sample processing: * tRNA extraction from all samples. * cDNA synthesis * Real time PCR performance.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. \- Mexican people. 2. \- Over 18 years of age. 3. \- With complete vaccination schedule against COVID-19. 4. \- Allowing peripheral blood samples to be taken. 5. \- To sign an informed consent form. 6. \- To agree to participate in the protocol.

Exclusion criteria

1. \- Persons with incomplete vaccination schedule against COVID-19. 2. \- Persons who have 30 +/- 5 days of having completed the vaccination scheme against COVID-19. 3. \- People under treatment with any immunosuppressive drug. 4. People who refuse to sign the informed consent form.

Design outcomes

Primary

Measure	Time frame	Description
Immunogenicity induced by COVID-19 vaccines in Mexican population	4 months	To characterize the immunogenicity induced by COVID-19 vaccines in Mexican population: mRNA expression for IgG anti-spike.

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026